سعر موكسيسارو 0.5% نقط للعين 10 مل 2025

Moxyseyaro 0.5% eye drops (10 ml bottle; Rameda > Talent Pharma, Egypt): moxifloxacin 0.5% ophthalmic solution, a fluoroquinolone antibacterial eye drop.

• Treatment of bacterial conjunctivitis caused by susceptible strains (e.g. Staphylococcus aureus, S. epidermidis, Streptococcus pneumoniae, viridans-group streptococci, Haemophilus influenzae, Chlamydia trachomatis and others listed in the US label).Population: Adults and children of all ages (including neonates) per US labelDailyMed (U.S. National Library of Medicine)

• Most frequent ocular adverse events (about 1%-6%): conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, hyperemia, pain, pruritus, subconjunctival hemorrhage and tearing. Non-ocular events (1%-4%): fever, increased cough, infection, otitis media, pharyngitis, rash and rhinitis.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• History of hypersensitivity to moxifloxacin, to other quinolones, or to any component of the medication.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity: serious, occasionally fatal anaphylactic reactions have been reported with systemically administered quinolones, including moxifloxacin, sometimes after the first dose; discontinue if an allergic reaction occurs.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Prolonged use may result in overgrowth of non-susceptible organisms, including fungi; if superinfection occurs, discontinue and use alternative therapy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Drugs metabolised by CYP3A4, CYP2D6, CYP2C9, CYP2C19 or CYP1A2No drug-drug interaction studies have been conducted with the ophthalmic solution; in vitro, moxifloxacin does not inhibit these CYP450 isozymes, so it is unlikely to alter the pharmacokinetics of drugs metabolised by them.DailyMed (U.S. National Library of Medicine)

• No adequate and well-controlled studies in pregnant women. Oral or intravenous moxifloxacin in pregnant rats, monkeys and rabbits during organogenesis produced no adverse maternal or fetal effects at clinically relevant doses; systemic exposure after ocular use is low.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk or effects on the breastfed infant; moxifloxacin passes into milk in lactating rats after oral dosing. Systemic levels after ocular use are low; weigh breastfeeding benefits against the mother's need for treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Moxifloxacin: Inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, enzymes required for bacterial DNA replication, transcription, repair and chromosome partitioning.